Schlaganfall und COVID-19

ZUSAMMENFASSUNG

Im Rahmen der COVID-19-Infektion kommt es bei 0,5% bis 2 % der betroffenen Patienten zu einem Schlaganfall. Die Schlaganfälle sind meist schwer mit ungünstiger Prognose. Bei den meisten Patienten handelt es sich um einen Verschluss der großen hirnversorgenden Arterien bedingt durch die COVID-19 induzierte Gerinnungsstörung. Im Rahmen der COVID-19-Infektion ist es vorübergehend zu einem dramatischen Rückgang von Schlaganfallpatienten gekommen, die in Stroke Units behandelt werden. Die Situation hat sich in der Zwischenzeit wieder normalisiert.

ABSTRACT

In the context of COVID-19 infection, 0.5% to 2 % of affected patients will suffer a stroke. The strokes are usually severe with an unfavorable prognosis. Most patients suffer from an occlusion of the large brain-supplying arteries caused by the COVID-19 induced coagulation disorder. In the context of COVID-19 infection, there has been a dramatic temporary decrease in the number of stroke patients treated in stroke units. The situation has since returned to normal.

Schlüsselwörter

COVID-19 - Schlaganfall - intrazerebrale Blutung - Pathophysiologie

Key words

Covid-19 - stroke - intracerebral hemorrhage - pathophysiology

• Literatur

• 1 Markus HS, Brainin M. COVID-19 and stroke-A global World Stroke Organization perspective. Int J Stroke 2020; 15 (04) 361-4
• 2 Kansagra AP, Goyal MS, Hamilton S. et al Collateral Effect of Covid-19 on Stroke Evaluation in the United States. New England Journal of Medicine 2020; 383 (04) 400-1
• 3 Berlit P. et al Neurologische Manifestationen bei COVID-19, S1-Leitlinie. 2020. In: Deutsche Gesellschaft für Neurologie (Hrsg.). Leitlinien für Diagnostik und Therapie in der Neurologie www.dgn.org/leitlinien Berlin:
• 4 Tan YK, Goh C, Leow AST. et al COVID-19 and ischemic stroke: a systematic review and meta-summary of the literature. J Thromb Thrombolysis 2020; 13: 1-9
• 5 Oxley TJ, Mocco J, Majidi S. et al Clinical Characteristics of Five Young Patients Presenting with Large-Vessel Stroke. NEJM 2020 doi.10.1056/NEJMc2009787
• 6 Ashrafi F, Zali A, Ommi D. et al COVID-19-related strokes in adults below 55 years of age: a case series. Neurol Sci 2020 www.springermedizin.de/covid-19/covid-19-related-strokes-in-adults-below-55-years-of-age-a-case-/18115882
• 7 Fan S, Xiao M, Han F, Xia P, Bai X, Chen H. et al Neurological Manifestations in Critically Ill Patients With COVID-19: A Retrospective Study. Frontiers in Neurology 2020; 11: 806
• 8 Hernandez-Fernandez F, Valencia HS, Barbella-Aponte RA. et al Cerebrovascular disease in patients with COVID-19: neuroimaging, histological and clinical description. Brain 2020 Jul 9;awaa239. doi: 10.1093/brain/awaa239
• 9 Yaghi S, Ishida K, Torres J. et al SARS-CoV-2 and Stroke in a New York Healthcare System. Stroke 2020; 51 (07) 2002-11
• 10 Paterson RW, Brown RL, Benjamin L. et al The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings. Brain 2020 academic.oup.com/brain/article/doi/10.1093/brain/awaa240/5868408
• 11 Mahammedi A, Saba L, Vagal A. et al Imaging in Neurological Disease of Hospitalized COVID-19 Patients: An Italian Multicenter Retrospective Observational Study. Radiology 2020 pubs.rsna.org/doi/10.1148/radiol.2020201933
• 12 Hess DC, Eldahshan W, Rutkowski E. COVID-19-Related Stroke. Translational Stroke Research 2020; 11 (03) 322-5
• 13 Beigel JH, Tomashek KM, Dodd LE. et al Remdesivir for the Treatment of Covid-19 – Preliminary Report. N Engl J Med 2020 May 22. doi: 10.1056/NEJMoa2007764
• 14 Grein J, Ohmagari N, Shin D. et al Compassionate Use of Remdesivir for Patients with Severe Covid-19. N Engl J Med 2020; 382: 2327-2336
• 15 Wang Y, Zhang D, Du G. et al Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. The Lancet 2020; 395 10236 1569-78
• 16 Recovery Collaborative Group Horby P, Lim WS. et al Dexamethasone in Hospitalized Patients with Covid-19 – Preliminary Report. N Engl J Med 2020 May 22, doi.10.1056/NEJMoa2007764
• 17 Pesavento R, Ceccato D, Pasquetto G. et al The hazard of (sub)therapeutic doses of anticoagulants in non-critically ill patients with Covid-19: the Padua province experience. J Thromb Haemost 2020 21 July. doi.org/10.1111/jth.15022